What Could Aprea Therapeutics'(NASDAQ:APRE) WEE1 Inhibitor Mean for Biomarker-Defined Cancers?

Sonal Goyal

05 November 2026 12:35 PM AEDT

What Could Aprea Therapeutics'(NASDAQ:APRE) WEE1 Inhibitor Mean for Biomarker-Defined Cancers?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured at the ENA 2026 symposium in Barcelona on November 20, 2026

• Phase 1 clinical trial expanded from three to nine active sites, with enrollment expected to reach six to ten patients per month in Q4 2026

• Cash and cash equivalents of $37.8 million as of September 30, 2026, with runway expected into Q1 2028

• Plans to evaluate APR-1051 in combination with pembrolizumab in HPV-positive head and neck squamous cell carcinoma

Aprea Therapeutics, Inc.(NASDAQ:APRE), a clinical-stage precision medicine oncology company, reported its financial results for the third quarter ended September 30, 2026, alongside a Business update on its lead candidate, APR-1051. The company is focused on developing targeted therapies for patients with biomarker-defined cancers, with its WEE1 inhibitor program serving as the centerpiece of its pipeline.

Clinical Development of APR-1051

APR-1051 is a potent and selective oral small molecule WEE1 inhibitor currently being evaluated in ACESOT-1051, a multi-center, open-label Phase 1 study. During the third quarter, the company expanded the clinical site network from three to nine active sites, with enrollment expected to reach six to ten patients per month by the fourth quarter of 2026. The company is concentrating on genetically defined cancers, with particular emphasis on endometrial cancers, including uterine serous carcinoma. This includes tumors characterized by PPP2R1A, CCNE1, CCNE2, or FBXW7 mutations and Cyclin E overexpression. The trial's primary objectives are safety, dose-limiting toxicity, maximum tolerated or administered dose, and recommended Phase 2 dose. Aprea plans to expand ACESOT-1051 to enroll at least 50 patients with uterine serous carcinoma or Cyclin E-overexpressing, platinum-resistant ovarian cancer, with completion of dose escalation and backfill expansion enrollment expected in the second quarter of 2027. The company also intends to evaluate APR-1051 in combination with pembrolizumab in HPV-positive head and neck squamous cell carcinoma.

Upcoming Data Presentations

Updated interim results from ACESOT-1051 will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), scheduled for November 20, 2026, in Barcelona, Spain. The presentation will be delivered by Timothy A. Yap, Ph.D., of The University of Texas MD Anderson Cancer Center, and will include updated clinical results beyond the May 6, 2026, data cutoff. The company noted preliminary antitumor activity and manageable tolerability observed to date support the strategy of advancing APR-1051 as a single agent in selected patient populations, while also evaluating rational combination approaches. The dose selection for Part 2 of the study, focused on dose optimization, remains on track for the first half of 2027.

Q3 2026 Financial Results

For the third quarter of 2026, Aprea reported Research and Development expenses that reflected the expansion of the ACESOT-1051 trial and the activation of additional clinical sites. The company expects R&D spending on APR-1051 to increase relative to prior plans as the trial expands. Cash and cash equivalents stood at $37.8 million as of September 30, 2026. The company expects this cash position to provide sufficient runway into the first quarter of 2028, supporting the execution of its clinical development strategy and the achievement of key milestones. On October 20, 2026, Aprea hosted a virtual research and development investor event focused on APR-1051 and its clinical development strategy. The company is positioning APR-1051 as a potentially differentiated, best-in-class WEE1 inhibitor for patients with biomarker-defined cancers.

The Road Ahead

Aprea Therapeutics enters the final stretch of 2026 with several near-term catalysts. The ENA 2026 oral presentation in November will provide the first updated look at ACESOT-1051 clinical data since the May cutoff. Site expansion and enrollment acceleration during Q4 are expected to support faster data generation. The company remains on track to select the Part 2 dose in the first half of 2027, with enrollment in the expansion cohort expected to complete in Q2 2027. With its cash runway extending into early 2028, Aprea has the financial capacity to advance through these milestones.

FAQs

Q: What is APR-1051 and what cancers is it targeting?

A: APR-1051 is an oral WEE1 inhibitor being developed for biomarker-defined cancers, with a focus on endometrial cancers including uterine serous carcinoma and Cyclin E-overexpressing tumors.

Q: How many clinical sites are currently active for the ACESOT-1051 trial?

A: The trial has been expanded from three to nine active sites, with enrollment expected to reach six to ten patients per month during Q4 2026.

Q: What is Aprea Therapeutics' cash runway?

A: The company had $37.8 million in cash and cash equivalents as of September 30, 2026, with expected runway into Q1 2028.

Q: When will updated clinical data for APR-1051 be presented?

A: Updated interim results will be featured in an oral presentation at the ENA 2026 symposium in Barcelona on November 20, 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.